Denali Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Denali Therapeutics Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation: Delaware
Headquarters city: South SAN Francisco
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: DNLI
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001714899
EIN: 46-3872213

Board of directors

Follow this board

David P. Schenkein · Director
Since 2023
Douglas G. Cole · Director
Since 2023
Erik Harris · Director
Since 2023
Felix Baker · Director Overboarded
Since 2025
Hauwermeiren Timothy Van · Director
Since 2025
Jay T. Flatley · Director
Since 2023
Jennifer E. Cook · Director
Since 2023
Julian Baker · Director Overboarded
Since 2025
Marc Tessier-Lavigne · Director
Since 2023
Nancy Thornberry · Director
Since 2023
Peter S. Klein · Director
Since 2023
Ryan J. Watts · Director · President and CEO
Since 2023
Steve E. Krognes · Director
Since 2023
Vicki L. Sato · Director
Since 2023

Chief executives

Ryan J. Watts · President and CEO

Dates unknown

Director election results

Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

13 of this board's directors also sit on 33 other boards. 30 are in the same sector.

Shared director Other board Same sector +17 more in the list below

ACADIA Pharmaceuticals Inc. Same sector
via Felix Baker and Julian Baker
BeOne Medicines Ltd. Same sector
via Felix Baker and Julian Baker
Bicycle Therapeutics plc Same sector
via Felix Baker and Julian Baker
DBV Technologies S.A. Same sector
via Felix Baker and Julian Baker
Immunocore Holdings plc Same sector
via Felix Baker and Julian Baker
Incyte Corp. Same sector
via Felix Baker and Julian Baker
Kiniksa Pharmaceuticals International plc Same sector
via Felix Baker and Julian Baker
Kodiak Sciences Inc Same sector
via Felix Baker and Julian Baker
Kymera Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Madrigal Pharmaceuticals Inc. Same sector
via Felix Baker and Julian Baker
Neurogene Inc. Same sector
via Felix Baker and Julian Baker
Prelude Therapeutics Incorporated Same sector
via Felix Baker and Julian Baker
Regeneron Pharmaceuticals Inc. Same sector
via David P. Schenkein and Marc Tessier-Lavigne
Replimune Group Inc. Same sector
via Felix Baker and Julian Baker
TScan Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
vTv Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Agios Pharmaceuticals Inc. Same sector
via David P. Schenkein
Allogene Therapeutics Inc. Same sector
via Vicki L. Sato
BridgeBio Pharma Inc. Same sector
via Jennifer E. Cook
F5 Inc.
via Peter S. Klein
Foghorn Therapeutics Inc. Same sector
via Douglas G. Cole
Guardant Health Inc. Same sector
via Steve E. Krognes
Jazz Pharmaceuticals plc Same sector
via Jennifer E. Cook
Lexeo Therapeutics Inc. Same sector
via Hauwermeiren Timothy Van
Palladyne AI Corp.
via Peter S. Klein
Pliant Therapeutics Inc. Same sector
via Steve E. Krognes
Prime Medicine Inc. Same sector
via David P. Schenkein
Rezolute Inc. Same sector
via Erik Harris
Rivian Automotive Inc.
via Jay T. Flatley
Sana Biotechnology Inc. Same sector
via Douglas G. Cole
Schrodinger Inc. Same sector
via Nancy Thornberry
Vertex Pharmaceuticals Incorporated Same sector
via Nancy Thornberry
Vir Biotechnology Inc. Same sector
via Vicki L. Sato

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $1,300,167; 7 sales by 4 insiders

Date	Insider	Transaction	Shares	Price	Value
Sep 4, 2026	Chin Peter Scott Officer (Chief Medical Officer)	Open-market sale	−1,654	$22.29	$36,868
Sep 2, 2026	Nancy Thornberry Director	Open-market sale	−10,824	$22.85	$247,328
Sep 2, 2026	Nancy Thornberry Director	Open-market sale	−615	$23.74	$14,600
Sep 1, 2026	Schuth Alexander O. Officer (COFO and Secretary)	Open-market sale	−2,768	$23.44	$64,882
Aug 12, 2026	Ryan J. Watts Director, Officer (President and CEO)	Gift	−32,220	—	—
Aug 11, 2026	Schuth Alexander O. Officer (COFO and Secretary)	Open-market sale	−2,857	$25.07	$71,625
Jun 3, 2026	Jay T. Flatley Director	Grant or award	+6,408	—	—
Jun 3, 2026	Peter S. Klein Director	Grant or award	+6,408	—	—
Jun 3, 2026	Steve E. Krognes Director	Grant or award	+6,408	—	—
Jun 3, 2026	David P. Schenkein Director	Grant or award	+6,408	—	—
Jun 3, 2026	Nancy Thornberry Director	Grant or award	+6,408	—	—
Jun 3, 2026	Hauwermeiren Timothy Van Director	Grant or award	+6,408	—	—
Jun 3, 2026	Jennifer E. Cook Director	Grant or award	+6,408	—	—
Jun 3, 2026	Baker Brothers Life Sciences LP Director	Grant or award	+6,408	—	—
Jun 3, 2026	Baker Brothers Life Sciences LP Director	Grant or award	+6,408	—	—

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Denali Therapeutics Inc.

Who is the CEO of Denali Therapeutics Inc.?

Ryan J. Watts is Denali Therapeutics Inc.'s President and CEO.

How many directors are on Denali Therapeutics Inc.'s board?

Denali Therapeutics Inc.'s board has 14 directors: David P. Schenkein, Douglas G. Cole, Erik Harris, Felix Baker, Hauwermeiren Timothy Van, Jay T. Flatley, Jennifer E. Cook, Julian Baker, Marc Tessier-Lavigne, Nancy Thornberry and 4 others.

Are Denali Therapeutics Inc. insiders buying or selling shares?

Over the last 12 months, Denali Therapeutics Inc. insiders made no open-market purchases and sold $1.3 million of shares in 7 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Denali Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="denali-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.